PET imaging of neuropathology in tauopathies: Progressive supranuclear palsy

Journal of Alzheimer's Disease

Volumn 36, Issue 1, 2013, Pages 145-153

  Kepe, Vladimir ^a   Bordelon, Yvette ^a   Boxer, Adam ^c   Huang, Sung Cheng ^a   Liu, Jie ^a   Thiede, Frederick C ^a   Mazziotta, John C ^a   Mendez, Mario F ^a,d   Donoghue, Natacha ^a,b   Small, Gary W ^a   Barrio, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

FDDNP; neuropathology; Parkinson's disease; positron emission tomography; progressive supranuclear palsy; tauopathy

Indexed keywords

2 [1 6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYLETHYLIDENE]MALONONITRILE F 18; AMYLOID BETA PROTEIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DISTRIBUTION VOLUME; GRAY MATTER; HUMAN; IN VIVO STUDY; MESENCEPHALON; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SUBTHALAMUS; TAUOPATHY; WHITE MATTER;

EID: 84878872401     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130032     Document Type: Article

References (35)

1. Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V, Barrio JR (2008) Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 7, 161-172.
2. Rowe CC, Villemagne V (2011) Brain amyloid imaging. J Nucl Med 52, 1733-1740.
3. Smid LM,Vovko TD, Popovic M, Petric A,Kepe V, Barrio JR, Vidmar G, BresjanacM(2006) The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol 16, 124-130.
4. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10, 24-35.
5. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355, 2652-2663.
6. Boxer AL, Rabinovici GD, Kepe V, Goldman J, Furst AJ, Huang SC, Baker SL, O'neil JP, Chui H, Geschwind MD, Small GW, Barrio JR, Jagust W, Miller BL (2007) Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 69, 283-290.
7. Kepe V, Ghetti B, Farlow MR, Bresjanac M, Miller K, Huang SC,Wong KP, Murrell JR, Piccardo P, Epperson F, Repovs G, Smid LM, Petric A, Siddarth P, Liu J, Satyamurthy N, Small GW, Barrio JR (2010) PET of brain prion protein amyloid in Gerstmann-Sträussler-Scheinker disease. Brain Pathol 20, 419-430.
8. Barrio JR, Satyamurthy N, Huang SC, Petric A, Small GW, Kepe V(2009) Dissecting molecular mechanisms in the living brain of dementia patients. Acc Chem Res 42, 842-850.
9. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL (2011) 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134, 1089-1100.
10. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, Yoshikawa T, Arai H, Iwata R, Kudo Y, Yanai K (2013) Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 40, 125-132.
11. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Su H, Szardenings AK, Walsh JC, Wang E, Yu C, Zhang W, Zhao T, Kolb HC (2013) [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement, doi: 10.1016/j.jalz.2012.11.008.
12. Villemagne V, Furumoto S, Fodero-Tavoletti M, Mulligan R, Hodges J, Kudo Y, Masters C, Yanai K, Rowe C, Okamura N (2012) In vivo tau imaging in Alzheimer's disease. J Nucl Med 53(Suppl 1), 36.
13. Chien DT, Bahri S, Szardenings AK,Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34, 457-468.
14. Tolnay M, Probst A (2003) The neuropathological spectrum of neurodegenerative tauopathies. IUBMB Life 55, 299-305.
15. Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T (2007) Pathological tau burden and distribution distinguishes progressive supranuclear palsyparkinsonism from Richardson's syndrome. Brain 130, 1566-1576.
16. Armstrong RA, Lantos PL, Cairns NJ (2007) Progressive supranuclear palsy (PSP): A quantitative study of the pathological changes in cortical and subcortical regions of eight cases. J Neural Transm 114, 1569-1577.
17. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 47, 1-9.
18. Golbe LI, Ohman-Strickland PA(2007)Aclinical rating scale for progressive supranuclear palsy. Brain 130, 1552-1565.
19. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
20. Fahn S, Elton RL, the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In Recent Developments in Parkinson's Disease, vol 2. Fahn S, Marsden CD, Calne D, Goldstein M, eds. Macmillan Healthcare Information, Florham Park, NJ, pp. 153-163.
21. Liu J, Kepe V, Zabjek A, Petric A, Padgett HC, Satyamurthy N, Barrio JR (2007) High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration. Mol Imaging Biol 9, 6-16.
22. Wardak M, Wong KP, Shao W, Dahlbom M, Kepe V, SatyamurthyN, Small GW, Barrio JR, Huang SC (2010)Movement correction method for human brain PET images: Application to quantitative analysis of dynamic 18F-FDDNP scans. J Nucl Med 51, 210-218.
23. Logan J, Fowler JS, Volkow ND,Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16, 834-840.
24. Kepe V, Huang SC, Small GW, Satyamurthy N, Barrio JR (2006) Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. Methods Enzymol 412, 144-160.
25. Jellinger K (2010) Cerebellar involvement in progressive supranuclear palsy. Mov Disord 25, 1104-1105.
26. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition Text Revision), American Psychiatric Association, Washington, DC.
27. Landau M, Sawaya MR, Faull KF, Laganowsky A, Jiang L, Sievers SA, Liu J, Barrio JR, Eisenberg D (2011) Towards the amyloid pharmacophore. PLoS Biology 9, e1001080.
28. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121-1159.
29. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E (2010) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A 97, 5129-5134.
30. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA (2010) Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 23, 394-400.
31. Arima K(2006) Ultrastructural characteristics of tau filaments in tauopathies: Immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 26, 475-483.
32. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44, 2015-2019.
33. Barrio JR, Bordelon Y, Small GW,Kepe V(2011)Visualizing tau pathology in the living brain of progressive supranuclear palsy patients, AD/PD 2011, Barcelona, Spain.
34. Shin J, Kepe V, Small GW, Phelps ME, Barrio JR (2011) Multimodal imaging of Alzheimer pathophysiology in the brain's default mode network. Int J Alzheimers Dis 2011, 687-945.
35. Small GW, Kepe V, Siddarth P, Ercoli LM, Merrill DA, Donoghue N, Bookheimer SY, Martinez J, Omalu B, Bailes J, Barrio JR (2013) PET scanning of brain tau in retired National Football League players: Preliminary findings. Am J Geriatr Psychiatry 21, 138-144.